Alliance, NCTN Actively Recruit Patients with Early-stage NSCLC to ALCHEMIST Trials

The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, is a group of clinical trials for patients with certain types of early-stage non-small cell lung cancer (NSCLC) that has been treated surgically. The ALCHEMIST trials involve genetic screening of tumor specimens removed during surgery for specific gene mutations and testing of adjuvant (post-operative) treatment with drugs that target those mutations but have only been approved by the U.S. Food and


UPCOMING MEETINGS

2015 Fall Group Meeting | November 4-8
2016 Fall Group Meeting | November 2-5
2017 Fall Group Meeting | November 1-4

Loews Chicago O'Hare Hotel, Rosemont, IL 60018
open to all Alliance members

TWEETS

FROM THE NCI

RSS Feed Widget